RegeneRx Biopharmaceuticals, Inc. ikunena kuti ochita kafukufuku awonetsa mphamvu zochiritsira za Thymosin Beta 4 (Tβ4) monga chithandizo chophatikizira motsutsana ndi hyperglycemia (diabetic) -zochititsa kusintha kwa maselo a cornea epithelial.
"Kafukufuku wathu akuwonetsa kwa nthawi yoyamba kuti chithandizo cha Tβ4 ndi vasoactive intestinal peptide (VIP) chimagwira ntchito yofunika kwambiri pakuwongolera kukhazikika kwapakati komanso kukonzanso kwa cytoskeleton [ya cornea], zomwe zimagwirizana kwambiri ndi kukhulupirika kwa zotchinga. Komanso, Tβ4 imakhazikitsa mwamphamvu ntchito yake monga chithandizo chothandizira matenda a shuga a cornea popanda zotsatirapo zake, motero kuchepetsa kuipa kwa njira zamakono [zosamalira maso]," malinga ndi gulu lofufuza.
Kafukufukuyu adaperekedwa pamsonkhano wa Association for Research in Vision and Ophthalmology (ARVO) 2022, womwe unachitikira May 1-4, 2022, ku Denver, Colorado. Gulu lofufuzira linaphatikizapo asayansi ndi madokotala ochokera ku Wayne State University School of Medicine ku Detroit, MI; University of Central Florida College of Health Professors and Sciences ku Orlando, FL; ndi Mansoura University ku Mansoura, Egypt. Kafukufukuyu adathandizidwa ndi National Institutes of Health, Eversight Center for Vision and Eye Banking Research, ndi Research to Prevent Blindness.
ZOMWE MUNGACHITE PA NKHANIYI:
- “Our study elucidates for the first time that a Tβ4 and vasoactive intestinal peptide (VIP) combo treatment plays a crucial role in regulating the tight junction stability and cytoskeleton rearrangement [of the cornea], which are closely related to barrier integrity.
- The research was presented at the Association for Research in Vision and Ophthalmology (ARVO) 2022 meeting, held May 1-4, 2022, in Denver, Colorado.
- is reporting that researchers have demonstrated the therapeutic efficacy of Thymosin Beta 4 (Tβ4) as a combination treatment against hyperglycemia (diabetic)-induced changes in human corneal epithelial cells.
